Scientists have identified several potential therapeutic targets for amyotrophic lateral sclerosis (ALS) using an artificial intelligence (AI)-powered target discovery engine to analyze dysregulated gene expression in large, publicly available ALS datasets.
About Anne D PhamThis author has not yet filled in any details.
So far Anne D Pham has created 63 blog entries.
Health Canada decision signifies the first global regulatory approval for Amylyx and the first new therapy for ALS approved in Canada since 2018 ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments In a clinical trial, ALBRIOZA significantly slowed disease progression and loss of functional decline in people living with ALS Detailed data from the CENTAUR clinical trial were published in the New England Journal of Medicine,Muscle & Nerve, and the Journal of Neurology, Neurosurgery and Psychiatry
Twelve-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength and quality of life Tofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegeneration SOD1-ALS is a rare, progressive and fatal genetic form of the disease leading to loss of everyday functions and affecting approximately 2% of people with ALS
ALS Finding a Cure® funded Eledon’s early clinical work for Tegoprubart when the drug was still with ALS TDIAnne D Pham2022-06-15T18:44:42+00:00
IRVINE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced topline results from a Phase 2a clinical trial of tegoprubart (formerly AT-1501) in patients with amyotrophic lateral sclerosis (ALS).1
The ALS Association, in collaboration with ALS Finding a Cure, recently awarded $400,000 to support research into the role SARM1 gene mutations play in the development and progression of ALS, with the ultimate goal of using an improved understanding of SARM1 to develop new treatments. The research will be led by Dr. Jemeen Sreedharan at King’s College London and Dr. Michael Coleman at Cambridge University.
Arrest ALS In collaboration with the ALS Association, we are pleased to announce the recent funding of four new grants designed to elucidate the biological linkages between key drivers of active axonal degeneration and ALS. ALS Finding a Cure® and the ALS Association are pleased to further scientific advances in this important area of research, which are sure to lead to future therapeutic insights. The four projects funded through the Arrest ALS collaboration include: Bloom/DiAntonio submission (Washington University in St. Louis): Pathological aggregation of the protein TDP-43 within motor neurons is seen in the majority of ALS cases (sporadic [...]
ALS Scholars in Therapeutics: Request for Applicants Please forward the announcement below to your network of clinical and basic researchers. Due date for nominations is April 29, 2022 The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) in partnership with ALS Finding a Cure® (ALSFAC) and FightMND is issuing a request for applications for the ALS Scholars in Therapeutics Program to empower young investigators to learn how to develop new treatments for people living with ALS. Full announcement can be found here. This two-year program is designed to engage clinician-scientists and post-doctoral fellows to gain training and experience in therapy [...]
Motor neuron toxin associated with ALS identified by UMass Chan investigators An international team of investigators has discovered that an inorganic polyphosphate released by nerve cells known as astrocytes in people with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) contributes to the motor neuron death that is the signature of these diseases. The research, by Brigitte van Zundert, PhD, adjunct professor of neurology at UMass Chan and professor at the Universidad Andres Bello in Chile; Robert H. Brown Jr., DPhil, MD, professor of neurology, and colleagues appears this week in Neuron.
Penn Medicine: Respiratory Care for ALS: The North American ALSFAC We Care Online Cource for CliniciansAnne D Pham2021-12-14T17:37:20+00:00
Penn Medicine: Respiratory Care for ALS: The North American ALSFAC We Care Online Cource for Clinicians Until the recent past, virtually everyone with amyotrophic lateral sclerosis (ALS) lost their breath as the paralyzing disease progressed. Most have died after 2 to 5 years of respiratory failure. However, extraordinary recent advances in respiratory care now enable many people with ALS to breathe comfortably and securely with the assistance of noninvasive (mask) ventilation throughout the course of their disease. Expertly managed noninvasive ventilation also prolongs survival and improves quality of life. Today, noninvasive ventilation remains the only therapy for ALS [...]
Hark-ALS: A Nationwide Network of Compassionate and Financial Resources for Families Living with ALSAnne D Pham2021-12-14T17:30:44+00:00
Hark-ALS: A Nationwide Network of Compassionate and Financial Resources for Families Living with ALS In 2009 I watched my dad slowly lose his ability to walk, talk, swallow and breathe before taking his last breath 18 months after being diagnosed with ALS (Lou Gehrig’s Disease). I’m one of 7 children and my dad was a veteran so we had all we needed to take care of him at home. Not long after my dad passed a good friend's husband was diagnosed with ALS; by the time he passed away she was financially devastated. My first thought was, “How [...]